<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS139869</article-id>
<article-id pub-id-type="doi">10.1101/2021.10.21.465252</article-id>
<article-id pub-id-type="archive">PPR411006</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Zhou</surname>
<given-names>Runhong</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wang</surname>
<given-names>Pui</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Wong</surname>
<given-names>Yik-Chun</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Xu</surname>
<given-names>Haoran</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lau</surname>
<given-names>Siu-Ying</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Li</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mok</surname>
<given-names>Bobo Wing-Yee</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Qiaoli</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A6">f</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Na</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Woo</surname>
<given-names>Kin-Fai</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Deng</surname>
<given-names>Shaofeng</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tam</surname>
<given-names>Rachel Chun-Yee</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Haode</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Anna Jinxia</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Dongyan</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Biao</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chan</surname>
<given-names>Chun-Yin</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Du</surname>
<given-names>Zhenglong</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Dawei</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Au</surname>
<given-names>Ka-Kit</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuen</surname>
<given-names>Kwok-Yung</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="aff" rid="A5">e</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Honglin</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="aff" rid="A5">e</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Zhiwei</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="aff" rid="A5">e</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>a</label>AIDS Institute, Li Ka Shing Faculty of Medicine, the University of Hong Kong; Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China</aff>
<aff id="A2">
<label>b</label>Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong; Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China</aff>
<aff id="A3">
<label>c</label>State Key Laboratory for Emerging Infectious Diseases, the University of Hong Kong; Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China</aff>
<aff id="A4">
<label>d</label>Centre for Virology, Vaccinology and Therapeutics Limited, the University of Hong Kong, Hong Kong Special Administrative Region, People’s Republic of China</aff>
<aff id="A5">
<label>e</label>Department of Clinical Microbiology and Infection Control, the University of Hong Kong-Shenzhen Hospital; Shenzhen, Guangdong, People’s Republic of China</aff>
<aff id="A6">
<label>f</label>National Clinical Research Center for Infectious Diseases, The Third People’s Hospital of Shenzhen and The Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong, People’s Republic of China</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>Correspondence: Zhiwei Chen (Lead contact), <email>zchenai@hku.hk</email> and Honglin Chen, <email>hlchen@hku.hk</email>. Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, L5-45, 21 Sassoon Road, Pokfulam, Hong Kong SAR, People’s Republic of China. Phone: 852-3917-9831; Fax: 852-3917-7805.</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>22</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>22</day>
<month>10</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Vaccines in emergency use are efficacious against COVID-19, yet vaccine-induced prevention against nasal SARS-CoV-2 infection remains suboptimal.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">Since mucosal immunity is critical for nasal prevention, we investigated an intramuscular PD1-based receptor-binding domain (RBD) DNA vaccine (PD1-RBD-DNA) and intranasal live attenuated influenza-based vaccines (LAIV-CA4-RBD and LAIV-HK68-RBD) against SARS-CoV-2.</p>
</sec>
<sec id="S3">
<title>Findings</title>
<p id="P3">Substantially higher systemic and mucosal immune responses, including bronchoalveolar lavage IgA/IgG and lung polyfunctional memory CD8 T cells, were induced by the heterologous PD1-RBD-DNA/LAIV-HK68-RBD as compared with other regimens. When vaccinated animals were challenged at the memory phase, prevention of robust SARS-CoV-2 infection in nasal turbinate was achieved primarily by the heterologous regimen besides consistent protection in lungs. The regimen-induced antibodies cross-neutralized variants of concerns. Furthermore, LAIV-CA4-RBD could boost the BioNTech vaccine for improved mucosal immunity.</p>
</sec>
<sec id="S4">
<title>Interpretation</title>
<p id="P4">Our results demonstrated that intranasal influenza-based boost vaccination is required for inducing mucosal and systemic immunity for effective SARS-CoV-2 prevention in both upper and lower respiratory systems.</p>
</sec>
<sec id="S5">
<title>Funding</title>
<p id="P5">This study was supported by the Research Grants Council Collaborative Research Fund (C7156-20G, C1134-20G and C5110-20G), General Research Fund (17107019) and Health and Medical Research Fund (19181052 and 19181012) in Hong Kong; Outbreak Response to Novel Coronavirus (COVID-19) by the Coalition for Epidemic Preparedness Innovations; Shenzhen Science and Technology Program (JSGG20200225151410198); the Health@InnoHK, Innovation and Technology Commission of Hong Kong; and National Program on Key Research Project of China (2020YFC0860600, 2020YFA0707500 and 2020YFA0707504); and donations from the Friends of Hope Education Fund. Z.C.’s team was also partly supported by the Theme-Based Research Scheme (T11-706/18-N).</p>
</sec>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>Receptor binding domain</kwd>
<kwd>Mucosal immunity</kwd>
<kwd>Nasal prevention</kwd>
<kwd>PD1-based DNA vaccine</kwd>
<kwd>Live-attenuated influenza-based vaccine</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S6" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p id="P6">Since the discovery of coronavirus disease 2019 (COVID-19) in human clusters in December 2019 (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>), the causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to over 100 million infections globally with nearly 2.1 million deaths after just one year. While the COVID-19 pandemic continues to evolve, hundreds of vaccine candidates have been brought into preclinical and clinical trials at an expedited speed using various platforms of technology (<xref ref-type="bibr" rid="R3">3</xref>–<xref ref-type="bibr" rid="R5">5</xref>). Encouragingly, several vaccines have now acquired regulatory approvals for emergency use in various countries, yet few have been evaluated for inducing mucosal protection, especially for preventing robust SARS-CoV-2 infection in nasal turbinate (NT) (<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>). NT in the upper respiratory tract (URT) is one of the most important portals of SARS-CoV-2 entry into humans. Ciliated nasal epithelial cells in NT have the highest expression of angiotensin-converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2), supporting rapid and robust SARS-CoV-2 infection (<xref ref-type="bibr" rid="R8">8</xref>). Unlike SARS patients who have peak viral load in URT at day 10 after symptom onset (<xref ref-type="bibr" rid="R9">9</xref>), COVID-19 patients exhibit the highest viral loads in URT at or soon after the clinical presentation (<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R10">10</xref>, <xref ref-type="bibr" rid="R11">11</xref>). Multiple SARS-CoV-2 variants can be transmitted simultaneously without a genetic bottleneck (<xref ref-type="bibr" rid="R12">12</xref>). Transmitted viruses then quickly impair host innate and adaptive immune responses (<xref ref-type="bibr" rid="R12">12</xref>), allowing for robust viral replication and asymptomatic viral spread. These findings indicated that the prevention of SARS-CoV-2 infection in NT is critical for pandemic control.</p>
<p id="P7">Current systemic vaccination and passive immunization are less effective or suboptimal for preventing SARS-CoV-2 in NT. Among vaccines authorized for emergency use, the Pfizer-BioNTech BNT162B2 mRNA, the Moderna mRNA-1273, the Oxford-ChAdOx1 and Novavax’s NVX-CoV2373 have released phase III results showing the efficacy of 95%, 94.1%, 70.4% and 89.3%, respectively, in preventing COVID-19 (<xref ref-type="bibr" rid="R13">13</xref>–<xref ref-type="bibr" rid="R15">15</xref>). The efficacy of the Oxford-ChAdOx1 vaccine against asymptomatic SARS-CoV-2 infection was only 3.8% among human vaccinees who received two standard doses (<xref ref-type="bibr" rid="R15">15</xref>). For passive immunotherapy, a receptor-binding domain (RBD)-specific human neutralizing antibody (NAb) LY-CoV555 has been evaluated in a phase 2 trial. Of three doses of 700 mg, 2800 mg and 7000 mg tested for monotherapy, only the medium dose of LY-CoV555 appeared to accelerate the natural decline of viral loads in nasopharyngeal swaps by day 11 (<xref ref-type="bibr" rid="R16">16</xref>). These results indicated that vaccine-induced or passive NAbs are suboptimal to prevent SARS-CoV-2 infection in human NT. Using the animal model, we reported that robust SARS-CoV-2 infection in NT may outcompete passive or vaccine-induced systemic NAbs, revealing a possible mechanism underlying the subprotection against asymptomatic infection (<xref ref-type="bibr" rid="R17">17</xref>). Considering that vaccine-induced subprotection may drive immune escape virus variants of concern and allow re-infection (<xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R20">20</xref>), we hypothesized that an effective vaccine should induce mucosal immunity for nasal protection to prevent SARS-CoV-2 asymptomatic infection and silent spread. Recently, thousands of vaccine-breakthrough infections in the United States have further indicated the need of priority research on nasal prevention of SARS-CoV-2 infection (<xref ref-type="bibr" rid="R21">21</xref>).</p>
</sec>
<sec id="S7" sec-type="methods">
<label>2</label>
<title>Methods</title>
<sec id="S8">
<label>2.1</label>
<title>Mice</title>
<p id="P8">Male and female BALB/c and K18-hACE2 mice (aged 6–10 weeks) were obtained from the HKU Laboratory Animal Unit (LAU). The animals were kept in Biosafety Level-2 housing and given access to standard pellet feed and water <italic>ad libitum</italic> following LAU’s standard operational procedures (SOPs). The viral challenge experiments were then conducted in our Biosafety Level-3 animal facility following SOPs strictly.</p>
</sec>
<sec id="S9">
<label>2.2</label>
<title>Cell lines</title>
<p id="P9">HEK 293T-hACE2 and Vero E6 cells (RRID:CVCL_0574) were maintained in Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher Scientific) containing 10% fetal bovine serum, 2 mM L-glutamine and 100 U/mL penicillin and were incubated at 37□ in 5% CO2 setting (<xref ref-type="bibr" rid="R22">22</xref>).</p>
</sec>
<sec id="S10">
<label>2.3</label>
<title>Viruses</title>
<p id="P10">Confluent Vero-E6 cells were infected at 0.01 MOI with live SARS-CoV-2 HKU-13 strain (GenBank accession number MT835140). After 3 days incubation, virus supernatant was collected for titration by plaque assay using Vero-E6 cells.</p>
</sec>
<sec id="S11">
<label>2.4</label>
<title>Construction and Generation of PD1-based DNA and live attenuated influenza virus (LAIV)-based vaccine</title>
<p id="P11">Codon-optimized SARS-CoV-2 RBD gene was in fusion to a human soluble PD1 domain (PD1-RBD) using the pVAX plasmid as the backbone. To maintain functional domains of the fusion protein, a linker (GGGGS)3 was applied between the PD1 and RBD gene (<xref ref-type="bibr" rid="R23">23</xref>). The expression construct contained a human tissue plasminogen activator (tPA) secretory signal sequence to promote antigen secretion. The plasmid DNA transfection into HEK 293T cells was performed using polyethylenimine (PEI), and protein expression was detected by Western blot. The pHW2000-DelNS1-RBD plasmid was constructed by inserting the tPA-linked RBD between the noncoding region (NCR) and autoproteolytic cleavage site (2A) in the pHW2000-DelNS1 plasmid. The V5 tag was added to the C terminal of RBD for better detection of RBD. To rescue the virus, eight pHW2000 plasmids containing the DelNS1-RBD and the other 7 influenza virus genomic segments, together with an NS1 expression plasmid, were transfected into 293T cells using Transit-LT1 (Mirus) according to the manufacturer protocol. After overnight incubation at 33 □, DNA mix was removed, and MEM supplemented with 1 μg/ml N-tosyl-L-phenylalanine chloromethyl ketone (TPCK)-treated trypsin (Sigma) was added. Virus supernatant was collected 72 hours later and designated passage 0 (p0) virus and was further passaged in chicken embryonated eggs for 48 hours at 33 □. Viruses were aliquoted and titrated by plaque assay using MDCK cells. Two intranasal recombinant LAIV DelNS1-RBD vaccine strains, namely LAIV-CA4-RBD and LAIV-HK68-RBD, were generated using A/CA/04/2009 (H1N1) and A/Hong Kong/1/68 (H3N2) surface proteins (HA and NA) in the A/CA/04/2009 (H1N1) DelNS1 backbone by a reverse genetic procedure (<xref ref-type="bibr" rid="R24">24</xref>).</p>
</sec>
<sec id="S12">
<label>2.5</label>
<title>Animal immunization and SARS-CoV-2 challenges</title>
<p id="P12">All animal experiments were approved by the Committee on the Use of Live Animals in Teaching and Research of the University of Hong Kong (HKU). For vaccine immunization, 6-8-weeks old BALB/c or K18-ACE2 transgenic mice received DNA immunization by intramuscular/electroporation (i.m./EP) with 50 μg PD1-RBD-DNA. The voltage of EP was pre-set 60 V in the TERESA DNA Delivery Device (Shanghai Teresa Healthcare Sci-Tech Co., Ltd). Mice intramuscularly received 1/5 clinical doses of Pfizer/BioNTech or Sinovac vaccine. Mice received LAIV-CA4-RBD or LAIV-HK68-RBD immunization by intranasal inoculation of 10<sup>6</sup> PFU per mouse at a 3-week interval under anesthesia. Blood sera was collected for anti-RBD IgG and neutralization detection. Mice were sacrificed and cells from lungs and spleen were harvested and subjected to intracellular cytokine staining (ICS) assay. For the SARS-CoV-2 challenge, BALB/c mice were anesthetized and transduced intranasally with 4×10<sup>8</sup> FFU of Ad5-hACE2, kindly provided by Dr. Jincun Zhao (<xref ref-type="bibr" rid="R25">25</xref>), in 70 μl DMEM. The transduced BALB/c mice or K18-ACE2 transgenic mice were intranasally infected with live wild type SARS-CoV-2 (HKU clone 13) at a dose of 1×10<sup>4</sup> PFU. Infected animals were sacrificed for endpoint analysis at day 4 post infection (4 dpi). All animal experiments related to SARS-CoV-2 were performed in a biosafety level 3 laboratory in HKU.</p>
</sec>
<sec id="S13">
<label>2.6</label>
<title>Enzyme-linked immunosorbent assay (ELISA)</title>
<p id="P13">ELISA was performed to detect SARS-CoV-2 RBD-specific IgG, as previously described (<xref ref-type="bibr" rid="R26">26</xref>). In brief, 96-well plates (Costar) were coated with recombinant SARS-CoV-2 RBD antigen (25 ng/well, Sino Biological) at 4°C overnight. After washing with PBST (0.05% Tween-20 in PBS), the plates were blocked with 4% skim milk in PBS for 1 hour at 37°C and incubated with serially diluted patient plasma for 1 hour at 37°C. After washing with PBST, goat anti-mouse IgG or anti-mouse IgA conjugated with HRP (Invitrogen) was added, and the whole solution was incubated for 1 hour, followed by washing and the addition of 50 μl HRP chromogenic substrate 3,3′,5,5′-TMB (Sigma). Optical density (OD) values were measured at 450 nm using the VARIOSKANTM LUX multimode microplate reader (Thermo Fisher Scientific). Area under the curve (AUC) was measured using GraphPad Prism v8, setting the baseline with the defined endpoint (average of negative control wells + 10 standard deviation) and taking the total peak area as previous described (<xref ref-type="bibr" rid="R27">27</xref>).</p>
</sec>
<sec id="S14">
<label>2.7</label>
<title>Pseudotyped viral neutralization assay</title>
<p id="P14">To determine the neutralizing activity of mouse sera and BAL, specimens were inactivated at 56□ for 30 min before the pseudotype viral entry assay as previously described (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R28">28</xref>). The results of this assay correlated strongly with that of neutralization assay using replication-competent SARS-CoV or SARS-CoV-2 (<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R29">29</xref>). The plasmids encoding for D614G, Alpha, Beta and Delta variants were kindly provided by Dr. David D. Ho. In brief, different SARS-CoV-2 pseudotype viruses were generated through co-transfection of 293T cells with 2 plasmids, pSARS-CoV-2 S and pNL4-3Luc_Env_Vpr, carrying the optimized SARS-CoV-2 S gene and a human immunodeficiency virus type 1 backbone, respectively. At 48 hours post-transfection, viral supernatant was collected and frozen at -80°C. Serially diluted serum samples were incubated with 200 TCID50 of pseudovirus at 37°C for 1 hour. The serum-virus mixtures were then added into pre-seeded HEK 293T-hACE2 cells. After 48 hours, infected cells were lysed, and luciferase activity was measured using Luciferase Assay System kits (Promega) in a Victor3-1420 Multilabel Counter (PerkinElmer). The 50% inhibitory concentrations (IC50) of each specimen were calculated using non-linear regression in GraphPad Prism v8 to reflect anti-SARS-CoV-2 potency.</p>
</sec>
<sec id="S15">
<label>2.8</label>
<title>Surface and intracellular cytokine staining (ICS)</title>
<p id="P15">The lung cells of mice were washed one time with staining buffer (PBS contained 2% FBS) followed by staining with anti-mouse antibodies for 30 min at 4 □, including dead cell dye (Zombie Aqua, Biolegend Cat# 423102), CD19-FITC (Biolegend Cat# 152404, RRID: AB_2629813), CD11b-PerCP/Cy5.5 (Biolegend Cat# 101228, RRID: AB_893232), CD11c-PE-Cy7 (Biolegend Cat# 117318, RRID: AB_493568), Ly6c-APC-Fire750 (BioLegend Cat# 128046, RRID: AB_2616731), F4/80-BV421 (Biolegend Cat# 123137, RRID: AB_2563102), Ly6G-PE (BioLegend Cat# 127608, RRID: AB_1186099), CD103-BV785 (Biolegend Cat# 121439,RRID:AB_2800588) and I-A/I-E-BV605 (Biolegend Cat# 107639, RRID: AB_2565894). To measure antigen-specific T cell response, lymphocytes from mouse lung and spleen were stimulated with 1 μg/mL SARS-CoV-2 RBD peptide pool (15-mer overlapping by 11, spanning the whole RBD sequence at Spike<sub>306-543</sub>). Cells were incubated at 37□ overnight, and BFA was added at 2 hours post-incubation. PMA/ionomycin stimulation was included as the positive control. After overnight incubation, cells were washed with staining buffer (PBS containing 2% FBS) and surface stained with anti-mouse-CD4-PerCP/Cy5.5 (Biolegend Cat# 116012, RRID:AB_2563023), anti-mouse-CD8-BV785 (Biolegend Cat# 100750, RRID: AB_2562610), anti-mouse CD69-BV711 (Biolegend Cat# 104537, RRID: AB_2566120) and anti-mouse CD103-BV421 (Biolegend Cat# 121422, RRID: AB_2562901). Zombie aqua staining was used to exclude dead cells. For intracellular staining, cells were fixed and permeabilized with BD Cytofix/Cytoperm (BD Biosciences) prior to staining with anti-mouse-IFN-γ-APC (Biolegend Cat# 505810, RRID: AB_315404), anti-mouse-TNF-α-PE (Biolegend Cat# 506306, RRID: AB_315427) and anti-mouse-IL-2-PE-Cy7 (Biolegend Cat# 503832, RRID: AB_2561750). Stained cells were acquired by FACSAriaIII Flow Cytometer (BD Biosciences) and analyzed with FlowJo software (v10.6) (BD Bioscience).</p>
</sec>
<sec id="S16">
<label>2.9</label>
<title>Viral RNA quantification</title>
<p id="P16">Half nasal turbinates and lung tissues were homogenized and subjected to viral load determination by quantitative SARS-CoV-2-specific RdRp/Hel reverse-transcription polymerase chain reaction assay (<xref ref-type="bibr" rid="R10">10</xref>). Total RNA was extracted using RNAeasy mini kit (Qiagen) and followed by reverse transcription (PrimeScript II 1<sup>st</sup> Strand cDNA Synthesis Kit). The real-time RT-PCR assay for SARS-CoV-2-RdRp/Hel RNA and NP subgenomic RNA detection was performed using One-Step TB Green PrimeScript RT-PCR Kit II according to the manufacture’s instruction. Mouse β-actin was used as normalization.</p>
</sec>
<sec id="S17">
<label>2.10</label>
<title>Plaque assay</title>
<p id="P17">Infectious virus titration was determined by plaque assay. Confluent Vero-E6 cells in a 12-well plate were incubated with 10-fold serially diluted tissue homogenates for 1 h. The virus supernatant was discarded, and cells were then overlaid with 1% agarose in DMEM and further incubated for 3 days at 37 °C followed by overnight fixation via 4% PFA. Agarose gels were removed, and plaques were visualized by 1 % crystal violet.</p>
</sec>
<sec id="S18">
<label>2.11</label>
<title>Histopathology and Immunofluorescence (IF) Staining</title>
<p id="P18">Tissues collected at necropsy were fixed in zinc formalin and then processed into paraffin-embedded tissue blocks. The tissue sections (4 μm) were stained with hematoxylin and eosin (H&amp;E) for light microscopy examination. For identification and localization of SARS-CoV-2 nucleocapsid protein (NP) in organ tissues, IF staining was performed on deparaffinized and rehydrated tissue sections using rabbit anti-SARS-CoV-2-N protein antibody together with AF568-conjugated goat anti-rabbit IgG (Invitrogen). Briefly, the tissue sections were first treated with antigen unmasking solution (Vector Laboratories) in a pressure cooker. After blocking with 0.1% Sudan black B for 15 min and 1% bovine serum albumin (BSA)/PBS at RT for 30 min, the primary antibody rabbit anti-SARS-CoV-2-N antibody (1:4000 dilution with 1% BSA/PBS) was incubated at 4°C overnight. This step was followed by AF568-conjugated goat anti-rabbit IgG for 30 min and then mounted with 4’,6-diamidino-2-phenylindole (DAPI). All tissue sections were examined, the images were captured with a Carl Zeiss LSM780 confocal microscope, and the mean fluorescence intensity (MFI) was further measured by ImageJ v1.53c.</p>
</sec>
<sec id="S19">
<label>2.12</label>
<title>Statistical analysis</title>
<p id="P19">Statistical analysis was performed with the GraphPad Prism 8 Software. Data represent mean values or mean values with SEM. Significant differences between the means of multiple groups were tested using a one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test. Significant differences between the two groups were performed using the 2-tailed Student’s t-test. P &lt; 0.05 was considered statistically significant.</p>
</sec>
<sec id="S20">
<label>2.13</label>
<title>Animal study approval</title>
<p id="P20">All experimental procedures were approved by the Committee on the Use of Live Animals in Teaching and Research (CULATR 5350-20) of the University of Hong Kong.</p>
</sec>
<sec id="S21">
<label>2.14</label>
<title>Role of funding source</title>
<p id="P21">The funders of this study had no role in study design, data collection, data analyses, interpretation, or writing of the report.</p>
</sec>
</sec>
<sec id="S22" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="S23">
<label>3.1</label>
<title>Construction and characterization of PD1-based DNA and influenza-based vaccines</title>
<p id="P22">To address the hypothesis, we sought to study an intramuscular program death 1 (PD1)-based RBD DNA vaccine (PD1-RBD-DNA) and two intranasal live attenuated influenza virus (LAIV)-based vaccines (LAIV-HK68-RBD and LAIV-CA4-RBD). Recently, Y Liu et al. demonstrated that antibodies against the N-terminal domain (NTD) could enhance the binding capacity of the spike protein to ACE2 and infectivity of SARS-CoV-2 (<xref ref-type="bibr" rid="R30">30</xref>). To avoid the potential full spike (S)-associated side effects (<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R31">31</xref>), we chose RBD as the vaccine immunogen. Since delayed cytotoxic T lymphocyte (CTL) responses are likely associated with COVID-19 severity (<xref ref-type="bibr" rid="R12">12</xref>), we constructed the PD1-RBD-DNA vaccine (<xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>) that might elicit enhanced antibody and CD8 T cell responses (<xref ref-type="bibr" rid="R23">23</xref>). The expression of soluble PD1-RBD protein (~80 kDa) was readily detected in supernatants of transfected HEK293T cells by Western blot analysis using either anti-SARS-CoV-2 RBD antibody (green lane) or anti-human PD-1 (red lane) antibody (<xref ref-type="supplementary-material" rid="SD1">Fig. S1B</xref>). The released PD1-RBD was able to bind PD-L (<xref ref-type="supplementary-material" rid="SD1">Fig. S1C</xref>), which might help antigen targeting to dendritic cells for cross-presentation (<xref ref-type="bibr" rid="R23">23</xref>). Meantime, the NS1-deleted (DelNS1) LAIV was engineered to express the same RBD (<xref ref-type="supplementary-material" rid="SD1">Fig. S1D</xref>), aiming to induce mucosal NAb and T cell immune responses (<xref ref-type="bibr" rid="R32">32</xref>). We previously characterized a panel of DelNS1 influenza viruses and evaluated their potential for being used as vaccine vectors (<xref ref-type="bibr" rid="R32">32</xref>). Two intranasal recombinant LAIV DelNS1-RBD vaccine strains, namely LAIV-CA4-RBD and LAIV-HK68-RBD, were generated using A/CA/04/2009 (H1N1) and A/Hong Kong/1/68 (H3N2) surface proteins (HA and NA) in the A/CA/04/2009 (H1N1) DelNS1 backbone by a reverse genetic procedure (<xref ref-type="bibr" rid="R24">24</xref>). The SARS-CoV-2 RBD and LAIV NP proteins were stably expressed in MDCK cells by Western blot after 5 times of viral passages in MDCK cells (<xref ref-type="supplementary-material" rid="SD1">Fig. S1E</xref>).</p>
</sec>
<sec id="S24">
<label>3.2</label>
<title>Systemic and mucosal antibody responses of vaccine regimens</title>
<p id="P23">We then chose the immune competent SARS-CoV-2/BALB/c mouse model (<xref ref-type="bibr" rid="R25">25</xref>), which was based on available antibody reagents to understand the potential correlate of immune protection. As compared with the vector control group (v1) that received 50 μg intramuscular electroporation (i.m./EP) pVAX plasmid prime plus i.n. 10<sup>6</sup> PFU LAIV-68 vector boost (<xref ref-type="fig" rid="F1">Fig. 1A</xref>), we tested groups treated by the homologous 50 μg i.m./EP PD1-RBD-DNA twice (v2), a heterologous i.n. 10<sup>6</sup> PFU LAIV-CA4-RBD prime plus i.n. 10<sup>6</sup> PFU LAIV-HK68-RBD boost (v3), a heterologous 50 μg i.m./EP PD1-RBD-DNA prime plus i.n. 10<sup>6</sup> PFU LAIV-68-RBD boost (v4) and a heterologous i.n. 10<sup>6</sup> PFU LAIV-CA4-RBD prime plus 50 μg i.m./EP PD1-RBD-DNA boost (v5) at 3-week intervals, consistent with COVID-19 vaccines under emergency use. Vaccine-induced antibody responses were determined at day 9 (acute phase) and day 69 (memory phase) post the second vaccination. Both peripheral blood and bronchoalveolar lavage (BAL) samples were collected from vaccinated mice for antibody detection by ELISA and pseudovirus neutralizing assays. We found that the PD1-RBD-DNA/LAIV-HK68-RBD regimen (v4) elicited and significantly sustained the highest amounts of RBD-specific IgG (acute: mean 5.2, range 4.86-5.45 logs AUC; memory: mean 4.62, range 4.54-4.69 logs AUC) and NAbs (acute: mean 4.19, 4.04-4.34 logs IC<sub>50</sub>; memory: mean 2.89, 2.4-3.23 logs IC<sub>50</sub>) in sera during both acute and memory phases as compared with other groups (<xref ref-type="fig" rid="F1">Fig. 1B-C</xref>). The RBD-specific IgG titer and NAb IC<sub>50</sub> values were correlated positively (<xref ref-type="fig" rid="F1">Fig. 1D</xref>), similar to COVID-19 patients’ sera (<xref ref-type="bibr" rid="R8">8</xref>). Moreover, v4 animals also developed and sustained significantly higher amounts of RBD-specific mucosal IgG and IgA in BAL during both acute and memory phases as compared with other groups (<xref ref-type="fig" rid="F1">Fig. 1E-F</xref>).The amount of BAL NAbs in v4 mice were at mean 2.80 (range 2.22-2.87) and mean 2.59 (range 2.02-3.15) logs IC<sub>50</sub> at the acute and memory phase, respectively (<xref ref-type="fig" rid="F1">Fig. 1G</xref>). In contrast, v2 and v5 elicited similar amounts of NAb to v4 at the acute phase, yet these responses did not sustain into the memory phase. Moreover, despite heterologous intranasal immunizations twice, the v3 regimen did not induce equally potent and sustained mucosal IgG and IgA as well as NAb responses, as compared with the v4 group (<xref ref-type="fig" rid="F1">Fig. 1G</xref>). Both BAL IgG and IgA titers correlated positively with the BAL NAb values (<xref ref-type="fig" rid="F1">Fig. 1H</xref>) despite of the higher amount and better acute/memory of BAL IgG than BAL IgA. Interestingly, serum NAb IC<sub>50</sub> values were correlated positively with the BAL NAbs IC<sub>50</sub> values at the memory phase, but not correlated at the acute phase (<xref ref-type="fig" rid="F1">Fig. 1I</xref>). These results indicated that the v4 regimen is likely unique for inducing potent and sustained systemic and mucosal memory IgG/IgA NAb responses.</p>
</sec>
<sec id="S25">
<label>3.3</label>
<title>Acute and memory T cell responses of vaccine regimens</title>
<p id="P24">Since SARS-CoV-2-specific T cell responses are essential for control and resolution of viral infection (<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R33">33</xref>), we sacrificed five groups of animals to measure vaccine-induced T cell immune responses at day 9 (acute phase) and day 69 (memory phase) post the second vaccination. Lymphocytes were isolated from both lungs (effector site) and spleens (secondary lymph organ) of vaccinated mice for comparison. We found that the v4 regimen elicited and sustained significantly higher frequencies of RBD-specific IFN-γ<sup>+</sup> CD8 T cells in lungs and spleens during both acute (<xref ref-type="fig" rid="F2">Fig. 2A-B</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S2A-B</xref>) and memory (<xref ref-type="fig" rid="F2">Fig. 2D-E</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S2D-E</xref>) phases as compared with other groups. Similar trends were found with IFN-γ<sup>+</sup> CD4 T cells elicited in the v4 regimen but at lower frequencies. At the acute phase, the v4 regimen elicited the highest mean frequency of RBD-specific IFN-γ<sup>+</sup> CD8 T cells (mean 28.83%, range 22-34.8%) in lungs (<xref ref-type="fig" rid="F2">Fig. 2B</xref>), which was even higher than that in spleens (mean 5.54%, range 3.63-7.06%) (<xref ref-type="supplementary-material" rid="SD1">Fig. S2B</xref>). These cells included the highest frequencies of polyfunctional CTLs with a capacity of releasing two (mean 21.09%, range 13.87-25.31%) or three (mean 2.27%, range 1.02-3%) cytokines (<xref ref-type="fig" rid="F2">Fig. 2C</xref>), which was also higher than those in splenic CD8 T cells releasing two (mean 6.68%, range 4.68-9.17%) or three cytokines (mean 0.92%, range 0.7-1.36%) (<xref ref-type="supplementary-material" rid="SD1">Fig. S2C</xref>). At the memory phase, the v4 regimen sustained the highest mean frequency of RBD-specific IFN-γ<sup>+</sup> CD8 T cells in lungs (mean 6.11%, range 2.05-9.7%) (<xref ref-type="fig" rid="F2">Fig. 2E</xref>) and spleens (mean 2.35%, range 0.7-4.78%) (<xref ref-type="supplementary-material" rid="SD1">Fig. S2E</xref>) as compared with other groups. These cells included the highest frequencies of polyfunctional CTLs with a capacity of releasing two (mean 8.66%, range 2.61-12.41%) or three (mean 2.2, range 0.66-3.09%) cytokines (<xref ref-type="fig" rid="F2">Fig. 2F</xref>), which was higher than those in splenic CD8 T cells releasing two (mean 3.59%, range 1.28-6.83%) or three cytokines (mean 0.69%, range 0.31-1.17%) (<xref ref-type="supplementary-material" rid="SD1">Fig. S2F</xref>). These results demonstrated that besides Nabs, the v4 regimen also induced potent and polyfunctional memory CD8 T cell responses, especially in lungs. Since overall immune responses induced by the heterologous v3 regimen were much weaker than those by the v4 regimen, we also exanimated T cell responses against influenza immunodominant nucleoprotein (NP) (<xref ref-type="bibr" rid="R34">34</xref>). At acute phase (<xref ref-type="supplementary-material" rid="SD1">Fig. S3A</xref>), the v3 regimen induced the highest frequencies of CD8 T cell response against influenza NP in lungs (mean 19.55%, range 16.2-21.7%) as compared with v1 (mean 8.3%, range 7.77-8.9%) and v5 (mean 3.99%, range 2.55-5.91%). Similar results were observed at the memory phase (<xref ref-type="supplementary-material" rid="SD1">Fig. S3B</xref>). In contrast, the v4 regimen induced significantly lower influenza NP-specific T cell response at both acute (mean 2.26%, range 1.68-2.58%) and memory (mean 0.77%, range 0.49-1.06%) phases. The heterologous prime using PD1-RBD-DNA instead of LAIV-CA4-RBD, therefore, offered an advantage in promoting the RBD immunodominance likely by avoiding anti-vector immune responses.</p>
</sec>
<sec id="S26">
<label>3.4</label>
<title>Protective efficacy against intranasal SARS-CoV-2 infection</title>
<p id="P25">To investigate the efficacy of various vaccine regimens against the live intranasal SARS-CoV-2 challenge, we subsequently immunized additional groups of BALB/c mice (n=6 per group) using the same doses and time interval as described above (<xref ref-type="fig" rid="F3">Fig. 3A</xref>). We did not include v5 due to low mucosal immunogenicity and limited space in our animal P3 facility. Sera were collected at day 9 and day 28 after the 2<sup>nd</sup> immunization to monitor anti-RBD IgG (<xref ref-type="fig" rid="F3">Fig. 3B</xref>) and neutralization (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). Consistently, the highest IgG (acute: mean 4.79, range 4.7-4.89 logs AUC; memory: mean 2.6, range 2.03-2.81 logs AUC) and neutralizing (acute: mean 3.9, range 3.69-4.14 logs IC<sub>50</sub>; memory: mean 2.94, range 2.34-3.33 logs IC<sub>50</sub>) titers were induced in mice by the v4 regimen at both acute and memory phases. Immunized mice were then transduced with Ad5-hACE2 at the memory phase, 29 days post the boost vaccination for expressing human ACE2 in nasal turbinate and lung (<xref ref-type="fig" rid="F3">Fig. 3D</xref>), followed by the intranasal SARS-CoV-2 challenge 6 days later as previously described (<xref ref-type="bibr" rid="R25">25</xref>). At day 4 after the viral challenge, mice were sacrificed for analysis. Lung specimen was harvested to quantify infectious viruses by plaque assay, viral load by real-time PCR (RT-PCR) and infected cells by immunofluorescence staining (IF). We found that all vaccinated animals had decreased infectious plaque-forming units (PFU) to the limit of detection (10 PFU/mL) in lungs (<xref ref-type="fig" rid="F3">Fig. 3E</xref>). The v4 regimen, however, resulted in the most significant genomic RdRp (gRdRp) drop in lungs by an average of 2.31 logs compared with 1.81 logs in v2 mice and 1.62 logs in v3 mice (<xref ref-type="fig" rid="F3">Fig. 3F</xref>). A similar observation was found in the measurement of nucleocapsid protein (NP) subgenomic RNA (sgNP) (<xref ref-type="fig" rid="F3">Fig. 3G</xref>). These findings demonstrated that immune responses induced by v2, v3 and v4 regimens had achieved significant protection in lungs. To determine viral infection in both upper and lower respiratory systems, we further performed immunofluorescence staining of SARS-CoV-2 NP antigen in both lung (<xref ref-type="fig" rid="F3">Fig. 3H</xref>) and NT (<xref ref-type="fig" rid="F3">Fig. 3I</xref>) tissues. Since murine NT was too small to be sliced for viral load tests, we only used it for the NP staining to maintain the necessary tissue structure. While significantly reduced NP<sup>+</sup> cells were observed in lungs of v2 and v3 mice, infected cells were barely found in lungs of v4 mice. Furthermore, no significantly reduced NP<sup>+</sup> cells were found in NT of v2 and v3 mice as compared with v1 mice, but only a few NP<sup>+</sup> cells were seen in v4 mice. Our results demonstrated that while protection was consistently found in lungs of vaccinated animals, significant prevention of robust SARS-CoV-2 infection in NT was only achieved by the v4 regimen.</p>
</sec>
<sec id="S27">
<label>3.5</label>
<title>Infection-recalled NAb for correlate of protection</title>
<p id="P26">Although we were not allowed to bring tissue specimens for measuring T cell immunity outside the animal P3 laboratory after the SARS-CoV-2 challenge, we managed to determine if viral infection recalled vaccine-induced NAbs for viral neutralization and clearance (<xref ref-type="bibr" rid="R35">35</xref>). By testing RBD-specific IgG and NAb at day 28 (before challenge) and day 39 (also 4 dpi) after the 2<sup>nd</sup> vaccination, we found that SARS-CoV-2 infection indeed recalled significantly anti-RBD IgG responses in all v2, v3 and v4 animals (<xref ref-type="supplementary-material" rid="SD1">Fig. S4A</xref>). Notably, 62.2-fold and 65.7-fold higher amounts of recalled NAb were found by the v4 regimen (v4, mean 4.64, range 3.22-5.03 logs IC<sub>50</sub>) than the v2 and v3, respectively (<xref ref-type="supplementary-material" rid="SD1">Fig. S4B</xref>). Furthermore, there were significant negative correlations between viral loads and IgG or NAb IC<sub>50</sub> values (<xref ref-type="supplementary-material" rid="SD1">Fig. S4C-D</xref>), as well as between NP<sup>+</sup> cells and IgG or NAb IC<sub>50</sub> values in lungs (<xref ref-type="supplementary-material" rid="SD1">Fig. S4E-F</xref>) and in NT (<xref ref-type="supplementary-material" rid="SD1">Fig. S4G-H</xref>). Moreover, since the T<sub>H</sub>1 immune response is likely associated with protective immune responses against COVID-19 (<xref ref-type="bibr" rid="R36">36</xref>), we also evaluated the ratios of IgG1 and IgG2a in all vaccinated mice. The v4 regimen likely induced a T<sub>H</sub>1 bias with a higher IgG2a/IgG1 ratio (mean 59.57, range 1.44-279.2) than those induced by v2 (mean 6.72, range 2.63-15.14) and v3 (mean 7.65, range 4.25-12.72) (<xref ref-type="supplementary-material" rid="SD1">Fig. S4I</xref>). Our results demonstrated that v4 vaccine-induced high amounts of NAbs correlated with protective efficacy in both NT and lung.</p>
</sec>
<sec id="S28">
<label>3.6</label>
<title>SARS-CoV-2 prevention in both upper and lower respiratory tracts of K18-hACE2 mice</title>
<p id="P27">To further determine the vaccine efficacy, we tested the PD1-RBD-DNA/LAIV-HK68-RBD regimen in K18-hACE2 transgenic mice, one of commonly used animal models for studying COVID-19 (<xref ref-type="bibr" rid="R37">37</xref>–<xref ref-type="bibr" rid="R39">39</xref>). 8-week-old K18-hACE2 mice were vaccinated with various regimens using the doses and time interval as described above (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). The titer of RBD-specific IgG (<xref ref-type="fig" rid="F4">Fig. 4B</xref>) and neutralization antibody (<xref ref-type="fig" rid="F4">Fig. 4C</xref>) was measured in serum at day-9 and day-33 (acute phase) after the 2<sup>nd</sup> immunization. Consistently, the PD1-RBD-DNA/LAIV-HK68-RBD regimen (v4) induced and sustained the highest amount of RBD-specific serum IgG (acute: mean 4.38, range 3.81-4.84 logs AUC; memory: mean 4.79, range 4.27-5.25 logs AUC) and Nabs (acute: mean 3.74, range 3.10-4.30 logs IC<sub>50</sub>; memory: mean 4.02, range 2.48-4.64 logs IC<sub>50</sub>) during both acute and memory phases as compared with other groups. At day 38 after the 2<sup>nd</sup> immunization, mice were intranasally challenged with 10<sup>4</sup> PFU of SARS-CoV-2 (HKU Clone 13). In lungs, no measurable infectious viruses (detection limit: 10 PFU/mL) were found in all v4 mice and 40% v2 mice, whereas infectious viruses were detected in all v1 and v3 mice (<xref ref-type="fig" rid="F4">Fig. 4D</xref>). The more sensitive RT-PCR further demonstrated that the v4 regimen resulted in the significant gRdRp drop by an average of 3.57 logs as compared with 0.81 logs in v2 mice and 0.25 logs in v3 mice (<xref ref-type="fig" rid="F4">Fig. 4E</xref>) at 4 dpi. A similar observation was found with the measurement of NP subgenomic RNA (<xref ref-type="fig" rid="F4">Fig. 4F</xref>). Importantly, no measurable infectious viruses were detected in nasal turbinate of v4 mice (<xref ref-type="fig" rid="F4">Fig</xref>. 4G) and the v4 regimen significantly suppressed viral genomic/subgenomic RNA (gRdRp and sgNP) (<xref ref-type="fig" rid="F4">Fig. 4H-I</xref>). Further IF staining of NP antigen confirmed that significantly reduced NP<sup>+</sup> cells were observed in both lungs (<xref ref-type="fig" rid="F4">Fig. 4K</xref>) and nasal turbinates (<xref ref-type="fig" rid="F4">Fig. 4L</xref>) of v4 mice as compared with other regimens. Daily monitoring of body weight after challenge showed that SARS-CoV-2 infection caused average 15%, 8% and 6% weight loss in v1, v2 and v3 mice at 4 dpi, respectively. In contrast, no weight loss was found in v4 mice during the experimental period (<xref ref-type="fig" rid="F4">Fig. 4J</xref>). To further characterize the injury of lung and nasal turbinate, we performed pathological analysis on specimens by haematoxylin and eosin (H&amp;E)-staining. Acute lung injury with peribronchiolar infiltration, alveolar space infiltration and exudation were visualized in v1 mice, while v2 and v3 mice showed less alveolar space infiltration. In contrast, only mild peribronchiolar infiltration was observed in v4 mice (<xref ref-type="fig" rid="F4">Fig. 4M</xref>). In nasal turbinate, damage of epithelium with extensive submucosal immune cell infiltration was observed in v1, v2 and v3 mice, but not in v4 mice (<xref ref-type="fig" rid="F4">Fig. 4N</xref>). Consistent results were found in the flow cytometry analysis of immune cell compositions in lungs. A significant decrease in frequency of alveolar macrophages as well as reduced CD103<sup>+</sup> DCs and CD11b<sup>+</sup> DCs (<xref ref-type="supplementary-material" rid="SD1">Fig. S5A-B</xref>) was found in the v4 mice as compared with other groups. These results in K18-hACE2 mice, therefore, further demonstrated that the PD1-RBD-DNA/LAIV-HK68-RBD regimen prevents robust SARS-CoV-2 infection not only in lung and but also in NT with minimal infection-associated inflammation and injury.</p>
</sec>
<sec id="S29">
<label>3.7</label>
<title>Both NAb and antigen-specific CD8 T cells associated with virus control in K18-hACE2 mice</title>
<p id="P28">Compare to the serum collected at day 5 before the challenge, the titer of RBD-specific IgG (<xref ref-type="fig" rid="F5">Fig. 5A</xref>) and NAb (<xref ref-type="fig" rid="F5">Fig. 5B</xref>) did not increase in sera collected at 4 dpi. We then assessed the T cell responses in lungs by RBD peptide re-stimulation, and a significant increase in IFN-γ producing CD8 T cells (mean 8.45%, range 6.76-10.4%) was observed in the lungs of the mice that received PD1-RBD-DNA prime/LAIV-HK68-RBD boost regimen (<xref ref-type="fig" rid="F5">Fig. 5C</xref>). Tissue-resident memory T cells (TRM) is a well-known antiviral T cell type that persists at mucosal sites (<xref ref-type="bibr" rid="R40">40</xref>). We found that a higher frequency of TRM cells (CD69<sup>+</sup>CD103<sup>+</sup>) (mean 30.1, range 17.6-40.9%) was identified in lung CD8 T cells in v4 mice (<xref ref-type="fig" rid="F5">Fig. 5D</xref>). Moreover, a higher frequency of IFN-γ<sup>+</sup> TRMs (mean 21.64%, range 17.1-26.3%) was found in v4 mice after RBD peptide re-stimulation (<xref ref-type="fig" rid="F5">Fig. 5E</xref>). Correlation analysis showed negative correlations between the NAb titer and viral load (RdRp RNA/NP<sup>+</sup> cells) and between the frequency of IFN-γ+ CD8 T cells and viral load in both lungs (<xref ref-type="fig" rid="F5">Fig. 5F</xref>) and nasal turbinate (<xref ref-type="fig" rid="F5">Fig. 5G</xref>), respectively, indicating their involvements in viral control.</p>
</sec>
<sec id="S30">
<label>3.8</label>
<title>LAIV-CA4-RBD boosted the immunogenicity of vaccines in emergency use</title>
<p id="P29">While we were studying the PD1-RBD-DNA/LAIV-HK68-RBD regimen, both the BioNTech mRNA vaccine and the Sinovac inactivated vaccine have been approved for emergency use in Hong Kong. Our LAIV-CA4-RBD vaccine is currently undergoing the phase I clinical trial in Hong Kong (ClinicalTrials.gov Identifier: NCT04809389). Since intramuscular administration of mRNA or inactivated vaccine induces mainly systemic IgG and some T cell immune responses without secretory IgA or tissue-resident memory T cells (<xref ref-type="bibr" rid="R41">41</xref>, <xref ref-type="bibr" rid="R42">42</xref>), we sought to determine if LAIV-CA4-RBD could boost their mucosal immunogenicity to provide the implication for clinical use. We, therefore, immunized additional groups of BALB/c mice as v7, v9, v8, v10 with a homologous <italic>i.m.</italic> BioNTech (1/5 of clinical dose), a homologous <italic>i.m.</italic> Sinovac (1/5 of clinical dose), a heterologous <italic>i.m.</italic> BioNTech plus 10<sup>6</sup> PFU LAIV-CA4-RBD, a heterologous <italic>i.m.</italic> Sinovac plus 10<sup>6</sup> PFU LAIV-CA4-RBD at a 3-week interval, respectively. The selection of the 1/5 of clinical dose was based on animal studies described previously (<xref ref-type="bibr" rid="R43">43</xref>). The control mice in v6 group were immunized by 50 μg i.m./EP PD1-RBD DNA plus LAIV-CA4-RBD as before (<xref ref-type="fig" rid="F6">Fig. 6A</xref>). At day 12 after the 2<sup>nd</sup> vaccination, serum and BAL were collected and subjected to detection of RBD-specific IgG and IgA as well as neutralization activity. Interestingly, v8 and v10 mice did not show increased titers of IgG and Nab in sera (<xref ref-type="fig" rid="F6">Fig. 6B, E</xref>), but had significantly increased titers of IgG (<xref ref-type="fig" rid="F6">Fig. 6C</xref>), IgA (<xref ref-type="fig" rid="F6">Fig. 6D</xref>) and Nab (<xref ref-type="fig" rid="F6">Fig. 6F</xref>) in BAL as compared with v7 and v9. We then assessed T cell responses in lungs by RBD peptide re-stimulation. A significant increase of IFN-γ producing CD8 T cells (mean 55.58%, range 44.9-65.1% in v8 and mean 2.16%, range 1.5-2.64% in v10) was found in mice that received the heterologous boost of LAIV-HK68-RBD than mice received homologous BioNTech or Sinovac (mean 22.14%, range 8.89-30.8% in v7 and mean 0.37, range 0.1-0.66% in v9) (<xref ref-type="fig" rid="F6">Fig. 6G</xref>). Furthermore, more total TRMs and RBD-specific TRMs were induced in v8 and v10 as compared with v7 and v9 (<xref ref-type="fig" rid="F6">Fig. 6G-H</xref>). These results demonstrated that the intranasal LAIV-CA4-RBD boost induced stronger humoral and cellular immune responses in mucosal sites than systemic vaccinations alone.</p>
</sec>
<sec id="S31">
<label>3.9</label>
<title>Vaccine-induced NAbs cross-neutralize global SARS-CoV-2 variants of concern</title>
<p id="P30">Recently emerged SARS-CoV-2 variants Alpha (B.1.1.7) from UK, Beta (B.1.351) from South Africa and Delta (B.1.167) from India have become challenges for passive immunotherapy and vaccine-induced protection (<xref ref-type="bibr" rid="R19">19</xref>, <xref ref-type="bibr" rid="R44">44</xref>). For example, the Novavax vaccine is effective against the wildtype SARS-CoV-2 (95.6%) but provides reduced protection against the variants Alpha (85.6%) and Beta (60%) (<xref ref-type="bibr" rid="R45">45</xref>). We, therefore, compared the neutralizing activity of immune sera from PD1-RBD-DNA/BioNTech/Sinovac prime and LAIV-CA4-RBD boosted mice (<xref ref-type="fig" rid="F6">Fig. 6</xref>) against pseudotyped viruses that contain the D614G, the Alpha, the Beta and the Delta variants (<xref ref-type="fig" rid="F7">Fig. 7A-B</xref>) as described previously (<xref ref-type="bibr" rid="R19">19</xref>). Compared to the D614G viral strain, v6 sera showed slightly enhanced neutralizing activity against the Alpha variant, while the sera of other groups exhibited reduced neutralization against the Alpha, Beta and Delta variants (<xref ref-type="fig" rid="F7">Fig. 7B</xref>). In line with a recent studies (<xref ref-type="bibr" rid="R19">19</xref>), the Beta and Delta variants were more resistant to neutralization by sera from all vaccine regimens with an average fold reduction of 1.5-1.77 (v6), 3.00-3.60 (v7), 1.98-2.03 (v8), 1.56-2.45 (v9) and 1.26-1.59 (v10) as compared to the D614G strain, respectively (<xref ref-type="fig" rid="F7">Fig. 7B</xref>). Although animals in the LAIV-CA4-RBD boost regimens (v6, v8 and v10) showed the mean 1.69-fold reduction against Beta or Delta variants, their mean NAb IC<sub>50</sub> titer of 1: 3633 (v6, range 1:1586-1:8250), 1:4370 (v8, range 1:2305-1:9068) and 1:3929 (v10, range 1:189-14393) remained high, respectively, which was superior or comparable to those of homologous-vaccinated mice as well as to the results of clinical vaccines against the wild type virus in murine models (<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R47">47</xref>). Importantly, the BAL from LAIV-CA4-RBD boost groups (v6, v8 and v10) were still able to neutralize the Beta and Delta variants (v6: mean 453, range 117-762; v8: mean 280, range 93-465; v10: mean 281, range 50-760) although they showed the average fold reduction of 2.64-2.90 (v6), 1.7-4.3 (v8) and 1.26-2.28 (v10) as compared to the D614G strain, respectively (<xref ref-type="fig" rid="F7">Fig. 7C-D</xref>). These results demonstrated that the systemic prime/LAIV boost regimen-induced high amounts of systemic and mucosal NAbs may confer cross-protection against the variants of concern before the tailor-made vaccines become available.</p>
</sec>
</sec>
<sec id="S32" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p id="P31">To control the ongoing COVID-19 pandemic, vaccine-induced protective immune responses should prevent SARS-CoV-2 nasal infection effectively to eliminate viral transmission between humans (<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R41">41</xref>). Failure of protection against SARS-CoV-2 in NT may allow asymptomatic viral spread and there have been over 10 thousand cases of vaccine breakthrough infections in the United States (<xref ref-type="bibr" rid="R45">45</xref>, <xref ref-type="bibr" rid="R48">48</xref>). To date, little is known about the correlate of vaccine-induced mucosal protection for the prevention of intranasal SARS-CoV-2 infection in animal models (<xref ref-type="bibr" rid="R15">15</xref>). In this study, we demonstrated that the intranasal LAIV-based vaccination is critical for boosting the systemic PD1-RBD-DNA vaccine prime for effective prevention of SARS-CoV-2 infection in both NT and lungs by inducing high amounts of mucosal IgA/IgG and polyfunctional memory CD8 T cells. Consistent with previous findings that a heterologous prime and boost vaccine regimen may induce stronger immune responses (<xref ref-type="bibr" rid="R49">49</xref>, <xref ref-type="bibr" rid="R50">50</xref>), our results on effective prevention of intranasal SARS-CoV-2 infection in NT would warrant the upcoming clinical development of PD1-based and LAIV-based COVID-19 vaccines (ClinicalTrials.gov Identifier: NCT04809389). Our findings may have significant implications to use LAIV-CA4-RBD for boosting the current vaccines under emergency use especially the extensively used nucleic acid-based COVID-19 vaccines (e.g. BioNTech mRNA).</p>
<p id="P32">The induction of mucosal immune responses is essential for preventing SARS-CoV-2 transmission effectively (<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R41">41</xref>). There are, however, some challenges underlying the prevention of SARS-CoV-2 in NT. First, SARS-CoV-2 exhibited a rapid burst of viral replication in NT (<xref ref-type="bibr" rid="R1">1</xref>), which has not been previously found with SARS-CoV (<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R51">51</xref>). Second, after viral entry, ciliated nasal epithelial cells with the highest expression of ACE2 and TMPRSS2 may facilitate more efficient cell-cell transmission (<xref ref-type="bibr" rid="R8">8</xref>), which probably makes it difficult for systemic NAb to block. Third, NAbs by systemic vaccination or passive immunization are less distributed on the surfaces of NT for the prevention of SARS-CoV-2 (<xref ref-type="bibr" rid="R17">17</xref>). Due to these challenges, it is critical to investigate vaccine-induced mucosal NAbs and CD8 T cells for SARS-CoV-2 prevention in NT. Thus far, most published vaccines have indicated excellent protective efficacy in the lungs of vaccinated animals without detailed analysis in NT (<xref ref-type="bibr" rid="R52">52</xref>–<xref ref-type="bibr" rid="R54">54</xref>). Several previous studies had shown no significant viral load drops in nasal swabs or nasal turbinates of vaccinated animals (<xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R43">43</xref>, <xref ref-type="bibr" rid="R55">55</xref>, <xref ref-type="bibr" rid="R56">56</xref>). One study found that optimal protection was achieved by only the DNA vaccine encoding the full S protein in both the upper and lower respiratory tracts against SARS-CoV-2 in rhesus macaques when vaccinated animals developed pseudovirus neutralizing IC<sub>50</sub> titer less than 1:1000 (<xref ref-type="bibr" rid="R57">57</xref>). Serum NAb titers, as measured by both pseudovirus and live virus neutralization, served as a significant correlate of protection. Similar protection in both the upper and lower respiratory tracts was achieved by the AD26 vaccine encoding the full S protein against SARS-CoV-2 in rhesus macaques in another study (<xref ref-type="bibr" rid="R56">56</xref>). Both studies, however, used the macaque model that requires inoculation of 10<sup>5</sup> TCID<sub>50</sub> SARS-CoV-2 into each nare and intratracheal for effective infection, which is not natural and is in great contrast to the robust nature of NT infection in humans. Using a DNA vaccine encoding the full S immunogen, we recently reported that there was significant protection in the lung but not in NT against SARS-CoV-2 in Syrian hamsters even though the vaccinated animals developed pseudovirus neutralizing IC<sub>50</sub> titer larger than 1:1000 (<xref ref-type="bibr" rid="R17">17</xref>). In this study, we consistently found that significant prevention of NT was not achieved by two systemic PD1-RBD-DNA vaccinations in both hACE2-tranduced mice and K18-hACE-2 mice.</p>
<p id="P33">For direct mucosal vaccination, a single-dose intranasal ChAd vaccine exhibited a significant reduction of viral loads in NT, yet the extent of infected cells in NT was not determined, and its potential for extensive human use remains unclear (<xref ref-type="bibr" rid="R39">39</xref>). Here, we showed the highest frequency of RBD-specific tissue-resident memory CD8 T cells in the respiratory system was found by the intranasal boost of LAIV-based vaccine after intramuscularly prime with various systemic vaccines (e.g. PD1-RBD-DNA, Pfizer/BioNTech and Sinovac). Moreover, besides RBD-specific tissue-resident memory CD8 T cells, we also observed the positive correlation between NAb IC<sub>50</sub> values and BAL NAb IC<sub>50</sub> values, and the negative correlation between NAb IC<sub>50</sub> values and NP<sup>+</sup> cells, especially in NT. It is encouraging to develop the LAIV-RBD vaccine as the boost vaccination combined with the prime of vaccines that were authorized for emergency use to achieve mucosal immunity against SARS-CoV-2. Furthermore, the role of the intranasal LAIV-RBD boost route in optimizing the extent and localization of humoral and cellular immune responses in mucosal site combined with systemic prime immunization is not clear yet and will be determined in the future study. For example, whether the intranasal LAIV-RBD boost can potently promote the antigen-specific T follicular helper cell responses as well as elicit the potent germinal center reaction for neutralizing antibody production in the mucosal site. Secondly, it is crucial to determine how the intranasal LAIV boost develops the antigen-specific tissue resident memory T cells which are not only destroy the infected cells but also recruit the innate and adaptive immune cells into the infected tissues via cytokines and chemokines (<xref ref-type="bibr" rid="R58">58</xref>).</p>
<p id="P34">In summary, our finding of prevention of NT against SARS-CoV-2 by the high amount and long-lasting mucosal NAbs and CD8 T cells induced by the heterologous PD1-RBD-DNA/LAIV-HK68-RBD regimen may have significant implication for COVID-19 pandemic control because of the existing mass-production industry for influenza vaccines. Meantime, one COVID-19 DNA vaccine has been approved for emergency use in India with promising results (<xref ref-type="bibr" rid="R59">59</xref>). Our PD1-RBD-DNA vaccine may prime stronger mucosal CD8 T cells responses besides benefits of inducing potent NAbs, better stability than mRNA vaccine, fast-tracked development and cost effective GMP production (<xref ref-type="bibr" rid="R60">60</xref>). Although intramuscular electroporation delivery has potential limitation for DNA vaccination in large populations, this approach has demonstrated the safety, tolerability and immunogenicity profile for SARS-CoV-2 DNA vaccines in clinical trials (<xref ref-type="bibr" rid="R61">61</xref>). Future study, however, is needed to develop non-invasive delivery techniques for DNA vaccination in humans. In addition, simultaneous or sequential co-infection by SARS-CoV-2 and A(H1N1)pdm09 caused more severe disease than infection by either virus (<xref ref-type="bibr" rid="R62">62</xref>), our LAIV platform may offer an opportunity of generating a human vaccine to fight both COVID-19 and influenza.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplemental meterials</label>
<media xlink:href="EMS139869-supplement-Supplemental_meterials.zip" mimetype="application" mime-subtype="zip" id="N67393" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S33">
<title>Acknowledgements</title>
<p>We thank Dr. Jincun Zhao for kindly providing the AD5-hACE2 construct, Drs. David D. Ho and Pengfei Wang for kindly providing the expression plasmids encoding for D614G, Alpha, Beta and Delta variants, and Shanghai Teresa Healthcare Sci-Tech Co., Ltd for providing the clinically certified TERESA-EPT-I Drug Delivery Device for DNA vaccination.</p>
</ack>
<sec id="S34" sec-type="data-availability">
<title>Data Sharing Statement</title>
<p id="P35">The authors declare that the data supporting the findings of this study are available from the corresponding author upon request.</p>
</sec>
<fn-group>
<fn id="FN1" fn-type="con">
<p id="P36">
<bold>Contributors</bold>
</p>
<p id="P37">Z.C. and H.C. supervised two collaborative teams, conceived of and designed the study, and wrote the manuscript. R.Z., P.W., Y.-C.W and H.X. designed the experiments, analysed the data, and prepared the manuscript. R.Z., P.W., Y-.C.W., H.X., S-. Y.L., B. W-.Y.M., K. F. W., H.H., R.C-.Y.T., and S.D. conducted the immunologic and virologic assays. L.L., A.Z. and D.Z. performed the immunofluorescence staining of animal tissue section. A.J.Z. analysed tissue pathology. Q.P., N.L., B.Z., C-.Y.C and D.Y. conducted the ELISA and neutralization assay, Z.D. and K-.K.A. performed the viral RNA measurement. K.-Y.Y. provided critical comments, supports and materials. Z.C. and R.Z. have accessed and verified the underlying data reported in the manuscript.</p>
</fn>
<fn id="FN2" fn-type="conflict">
<p id="P38">
<bold>Declaration of Interests</bold>
</p>
<p id="P39">H.C., Z.C. and KY.Y. are co-inventors of PD1-based and LAIV-based COVID-19 vaccine patent. YC. W. and L.L are co-inventors of PD1-based COVID-19 vaccine, P.W. is co-inventors of LAIV-based COVID-19 vaccine. The other authors declare no competing interests.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>To</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Tsang</surname>
<given-names>OT</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Lung</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group>
<article-title>Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study</article-title>
<source>Lancet Infect Dis</source>
<year>2020</year>
<volume>20</volume>
<issue>5</issue>
<fpage>565</fpage>
<lpage>74</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>382</volume>
<issue>8</issue>
<fpage>727</fpage>
<lpage>33</lpage>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walsh</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Frenck</surname>
<given-names>RW</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Falsey</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Kitchin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Absalon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gurtman</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<issue>25</issue>
<fpage>2439</fpage>
<lpage>50</lpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogel</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Kanevsky</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Muik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vormehr</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Immunogenic BNT162b vaccines protect rhesus macaques from SARS-CoV-2</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anderson</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Rouphael</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Widge</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Makhene</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<issue>25</issue>
<fpage>2427</fpage>
<lpage>38</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Leist</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Abiona</surname>
<given-names>OM</given-names>
</name>
<name>
<surname>Boyoglu-Barnum</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>RA</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<issue>7830</issue>
<fpage>567</fpage>
<lpage>71</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Doremalen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Lambe</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Belij-Rammerstorfer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Purushotham</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Port</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group>
<article-title>ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<issue>7830</issue>
<fpage>578</fpage>
<lpage>82</lpage>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>To</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>KY</given-names>
</name>
<etal/>
</person-group>
<article-title>High neutralizing antibody titer in intensive care unit patients with COVID-19</article-title>
<source>Emerg Microbes Infect</source>
<year>2020</year>
<volume>9</volume>
<issue>1</issue>
<fpage>1664</fpage>
<lpage>70</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peiris</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Poon</surname>
<given-names>LL</given-names>
</name>
<etal/>
</person-group>
<article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title>
<source>Lancet</source>
<year>2003</year>
<volume>361</volume>
<issue>9371</issue>
<fpage>1767</fpage>
<lpage>72</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>To</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>KH</given-names>
</name>
<etal/>
</person-group>
<article-title>Improved Molecular Diagnosis of COVID-19 by the Novel, Highly Sensitive and Specific COVID-19-RdRp/Hel Real-Time Reverse Transcription-PCR Assay Validated In Vitro and with Clinical Specimens</article-title>
<source>J Clin Microbiol</source>
<year>2020</year>
<volume>58</volume>
<issue>5</issue>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>IF</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>VC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>KH</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series</article-title>
<source>Lancet Infect Dis</source>
<year>2020</year>
<volume>20</volume>
<issue>9</issue>
<fpage>1051</fpage>
<lpage>60</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Wang To</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>BWY</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>
<article-title>Natural transmission of bat-like SARS-CoV-2PRRA variants in COVID-19 patients</article-title>
<source>Clin Infect Dis</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polack</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Kitchin</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Absalon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gurtman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lockhart</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<issue>27</issue>
<fpage>2603</fpage>
<lpage>15</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baden</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>El Sahly</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Essink</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kotloff</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Frey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Novak</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>384</volume>
<issue>5</issue>
<fpage>403</fpage>
<lpage>16</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voysey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Clemens</surname>
<given-names>SAC</given-names>
</name>
<name>
<surname>Madhi</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Weckx</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Folegatti</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Aley</surname>
<given-names>PK</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title>
<source>Lancet</source>
<year>2021</year>
<volume>397</volume>
<issue>10269</issue>
<fpage>99</fpage>
<lpage>111</lpage>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nirula</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Heller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gottlieb</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Boscia</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19</article-title>
<source>N Engl J Med</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hie</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bryson</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Learning the language of viral evolution and escape</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
<issue>6526</issue>
<fpage>284</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Iketani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folegatti</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Ewer</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Aley</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Angus</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Belij-Rammerstorfer</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>396</volume>
<issue>10249</issue>
<fpage>467</fpage>
<lpage>78</lpage>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birhane</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bressler</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dorough</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fischer</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021</article-title>
<source>MMWR Morb Mortal Wkly Rep</source>
<year>2021</year>
<volume>70</volume>
<fpage>792</fpage>
<lpage>3</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kwok</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection</article-title>
<source>JCI Insight</source>
<year>2019</year>
<volume>4</volume>
<issue>4</issue>
<elocation-id>e123158</elocation-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice</article-title>
<source>J Clin Invest</source>
<year>2013</year>
<volume>123</volume>
<issue>6</issue>
<fpage>2629</fpage>
<lpage>42</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X</given-names>
</name>
<etal/>
</person-group>
<article-title>An A14U Substitution in the 3′ Noncoding Region of the M Segment of Viral RNA Supports Replication of Influenza Virus with an NS1 Deletion by Modulating Alternative Splicing of M Segment mRNAs</article-title>
<source>J Virol</source>
<year>2015</year>
<volume>89</volume>
<issue>20</issue>
<fpage>10273</fpage>
<lpage>85</lpage>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhuang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<issue>3</issue>
<fpage>734</fpage>
<lpage>43</lpage>
<elocation-id>e5</elocation-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>An</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice</article-title>
<source>J Clin Invest</source>
<year>2018</year>
<volume>128</volume>
<issue>6</issue>
<fpage>2239</fpage>
<lpage>51</lpage>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Foulds</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Francica</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Boyoglu-Barnum</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>AP</given-names>
</name>
<etal/>
</person-group>
<article-title>Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates</article-title>
<source>N Engl J Med</source>
<year>2020</year>
<volume>383</volume>
<issue>16</issue>
<fpage>1544</fpage>
<lpage>55</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>He</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>CE</given-names>
</name>
<etal/>
</person-group>
<article-title>Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals</article-title>
<source>J Med Virol</source>
<year>2006</year>
<volume>78</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Temperton</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zambon</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Tedder</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes</article-title>
<source>Emerg Infect Dis</source>
<year>2005</year>
<volume>11</volume>
<issue>3</issue>
<fpage>411</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Soh</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Kishikawa</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Hirose</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nakayama</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies</article-title>
<source>Cell</source>
<year>2021</year>
<volume>184</volume>
<issue>13</issue>
<fpage>3452</fpage>
<lpage>66</lpage>
<elocation-id>e18</elocation-id>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsen</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>de Graaf</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Sonneveld</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Plomp</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Nouta</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hoepel</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Afucosylated IgG characterizes enveloped viral responses and correlates with COVID-19 severity</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
<issue>6532</issue>
<fpage>907</fpage>
<comment>-+</comment>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lau</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mok</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines</article-title>
<source>mBio</source>
<year>2019</year>
<volume>10</volume>
<issue>5</issue>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Crotty</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Adaptive immunity to SARS-CoV-2 and COVID-19</article-title>
<source>Cell</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>LY</given-names>
</name>
<name>
<surname>Ha do</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>C</given-names>
</name>
<name>
<surname>de Jong</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Chau</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>Schumacher</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals</article-title>
<source>J Clin Invest</source>
<year>2008</year>
<volume>118</volume>
<issue>10</issue>
<fpage>3478</fpage>
<lpage>90</lpage>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poland</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Ovsyannikova</surname>
<given-names>IG</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>396</volume>
<issue>10262</issue>
<fpage>1595</fpage>
<lpage>606</lpage>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sahin</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Muik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Derhovanessian</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vogler</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kranz</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Vormehr</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<issue>7830</issue>
<fpage>594</fpage>
<lpage>9</lpage>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winkler</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Bailey</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kafai</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McCune</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function</article-title>
<source>Nat Immunol</source>
<year>2020</year>
<volume>21</volume>
<issue>11</issue>
<fpage>1327</fpage>
<lpage>35</lpage>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Wohlford-Lenane</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice</article-title>
<source>Nature</source>
<year>2021</year>
<volume>589</volume>
<issue>7843</issue>
<fpage>603</fpage>
<lpage>7</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Kafai</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Dmitriev</surname>
<given-names>IP</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>IB</given-names>
</name>
<etal/>
</person-group>
<article-title>A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<issue>1</issue>
<fpage>169</fpage>
<lpage>84</lpage>
<elocation-id>e13</elocation-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paik</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Farber</surname>
<given-names>DL</given-names>
</name>
</person-group>
<article-title>Anti-viral protective capacity of tissue resident memory T cells</article-title>
<source>Curr Opin Virol</source>
<year>2021</year>
<volume>46</volume>
<fpage>20</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krammer</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 vaccines in development</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<issue>7830</issue>
<fpage>516</fpage>
<lpage>27</lpage>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mora</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>von Andrian</surname>
<given-names>UH</given-names>
</name>
</person-group>
<article-title>T-cell homing specificity and plasticity: new concepts and future challenges</article-title>
<source>Trends Immunol</source>
<year>2006</year>
<volume>27</volume>
<issue>5</issue>
<fpage>235</fpage>
<lpage>43</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vogel</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Kanevsky</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Muik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vormehr</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>BNT162b vaccines protect rhesus macaques from SARS-CoV-2</article-title>
<source>Nature</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Muik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wallisch</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Sanger</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Swanson</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Muhl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera</article-title>
<source>Science</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mahase</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant</article-title>
<source>BMJ</source>
<year>2021</year>
<volume>372</volume>
<fpage>n296</fpage>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Haupt</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Weston</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<issue>1</issue>
<fpage>372</fpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Graham</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>McLean</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Belij-Rammerstorfer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ulaszewska</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19</article-title>
<source>NPJ Vaccines</source>
<year>2020</year>
<volume>5</volume>
<fpage>69</fpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandon</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mackinnon</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Nee</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Read</surname>
<given-names>AF</given-names>
</name>
</person-group>
<article-title>Imperfect vaccines and the evolution of pathogen virulence</article-title>
<source>Nature</source>
<year>2001</year>
<volume>414</volume>
<issue>6865</issue>
<fpage>751</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>YC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>SMY</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>AKL</given-names>
</name>
<etal/>
</person-group>
<article-title>DNA prime/MVTT boost regimen with HIV-1 mosaic Gag enhances the potency of antigen-specific immune responses</article-title>
<source>Vaccine</source>
<year>2018</year>
<volume>36</volume>
<issue>31</issue>
<fpage>4621</fpage>
<lpage>32</lpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ba</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
</person-group>
<article-title>Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus</article-title>
<source>Appl Microbiol Biotechnol</source>
<year>2007</year>
<volume>76</volume>
<issue>5</issue>
<fpage>1131</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Nishiura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Midkiff</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques</article-title>
<source>Mucosal Immunol</source>
<year>2016</year>
<volume>9</volume>
<issue>4</issue>
<fpage>1089</fpage>
<lpage>101</lpage>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>
<article-title>Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<issue>3</issue>
<fpage>713</fpage>
<lpage>21</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<issue>6499</issue>
<fpage>77</fpage>
<lpage>81</lpage>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Tong</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<issue>1</issue>
<fpage>776</fpage>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Routhu</surname>
<given-names>NK</given-names>
</name>
<name>
<surname>Cheedarla</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gangadhara</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bollimpelli</surname>
<given-names>VS</given-names>
</name>
<name>
<surname>Boddapati</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Shiferaw</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs</article-title>
<source>Immunity</source>
<year>2021</year>
<volume>54</volume>
<issue>3</issue>
<fpage>542</fpage>
<lpage>56</lpage>
<elocation-id>e9</elocation-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mercado</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>Zahn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wegmann</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Loos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chandrashekar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title>
<source>Nature</source>
<year>2020</year>
<volume>586</volume>
<issue>7830</issue>
<fpage>583</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tostanoski</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mercado</surname>
<given-names>NB</given-names>
</name>
<name>
<surname>McMahan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mahrokhian</surname>
<given-names>SH</given-names>
</name>
<etal/>
</person-group>
<article-title>DNA vaccine protection against SARS-CoV-2 in rhesus macaques</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<issue>6505</issue>
<fpage>806</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morabito</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Ruckwardt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Redwood</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Moin</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Price</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Intranasal administration of RSV antigen-expressing MCMV elicits robust tissue-resident effector and effector memory CD8+T cells in the lung</article-title>
<source>Mucosal Immunology</source>
<year>2017</year>
<volume>10</volume>
<issue>2</issue>
<fpage>545</fpage>
<lpage>54</lpage>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Momin</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kansagra</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India</article-title>
<source>EClinicalMedicine</source>
<year>2021</year>
<volume>38</volume>
<elocation-id>101020</elocation-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mallapaty</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>India’s DNA Covid Vaccine Is a World First - More Are Coming</article-title>
<source>Nature</source>
<year>2021</year>
<volume>597</volume>
<issue>7875</issue>
<fpage>161</fpage>
<lpage>2</lpage>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tebas</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Boyer</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Reuschel</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Christensen-Quick</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial</article-title>
<source>EClinicalMedicine</source>
<year>2021</year>
<volume>31</volume>
<elocation-id>100689</elocation-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Co-infection by severe acute respiratory syndrome coronavirus 2 and influenza A(H1N1)pdm09 virus enhances the severity of pneumonia in golden Syrian hamsters</article-title>
<source>Clin Infect Dis</source>
<year>2020</year>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>1. Vaccine-induced systemic and mucosal antibody responses.</title>
<p>(<bold>A</bold>) Vaccine immunization schedule and grouping for BALB/c mice (n=8/group). Blood and bronchoalveolar lavage (BAL) were collected and subjected to antibody response analysis at 9 (acute phase, n=4/group) or 69 (memory phase, n=4/group) days post the 2nd immunization, respectively. In sera, (<bold>B</bold>) RBD-specific IgG titer, (<bold>C</bold>) NAb IC<sub>50</sub> values and (<bold>D</bold>) positive correlations between RBD-specific IgG titer and NAb IC50 values were analyzed for both acute and memory phases. In BAL, (<bold>E</bold>) RBD-specific IgG titer, (<bold>F</bold>) RBD-specific IgA titer, (<bold>G</bold>) NAb IC<sub>50</sub> values and (<bold>H</bold>) positive correlations between RBD-specific IgG (square) or IgA titers (triangle) and BAL NAb IC<sub>50</sub> values were analyzed for both acute and memory phases. (<bold>I</bold>) Correlate analysis between Peripheral NAb IC<sub>50</sub> values and BAL NAb IC50 values at both acute and memory phase. RBD-specific IgG or IgA titers were determined by ELISA at serial dilutions. The area under the curve (AUC) represented the total peak area calculated from ELISA OD values. Neutralization IC<sub>50</sub> values were determined against SARS-CoV-2-Spike-pseudovirus infection of 293T-huACE2 cells. Correlation analysis was performed by linear regression using GraphPad Prism 8.0. Each symbol represents an individual mouse with color-coding for corresponding groups. Error bars indicate the standard error of the mean. Statistics were generated using one-way ANOVA followed by Tukey’s multiple comparisons test. *p&lt;0.05; **p&lt;0.01.</p>
</caption>
<graphic xlink:href="EMS139869-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>Vaccine-induced acute and memory T cell responses in lungs.</title>
<p>The vaccine immunization schedule for BALB/c mice was the same as described in <xref ref-type="fig" rid="F1">Fig. 1A</xref>. Cells from lungs were collected and subjected to SARS-CoV-2 RBD-specific T cell responses by <italic>ex vivo</italic> RBD peptide pool stimulation followed by ICS at both acute (<bold>A-C</bold>) and memory (<bold>D-F</bold>) phase. (<bold>A, D</bold>) Representative dot plots present the gating of IFN-γ<sup>+</sup>, TNF-α<sup>+</sup> or IL-2<sup>+</sup> CD4 T (left) and CD8 T (right) against SARS-CoV-2 RBD. (<bold>B, E</bold>) Quantified results depict the percentage of IFN-γ<sup>+</sup> CD4 T (left) and IFN-γ<sup>+</sup> CD8 T (right). Each symbol represents an individual mouse. Error bars indicate the standard error of the mean. (<bold>C, F</bold>) The pie charts indicate the proportion of single or double or triple cytokines produced by CD4 T (left) and CD8 T (right). Statistics were generated using one-way ANOVA followed by Tukey’s multiple comparisons test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p>
</caption>
<graphic xlink:href="EMS139869-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>Protective efficacy of vaccine regimens in huACE2-transduced mice.</title>
<p>(<bold>A</bold>) Experimental schedule and grouping of BALB/c mice (6 mice/group). At day 29 post the 2<sup>nd</sup> immunization, mice were transduced to express human ACE2 in vivo by inoculating 4×10<sup>8</sup> plaque-forming units (PFU) Ad5-hACE2 intranasally. Six days later, mice were challenged intranasally with 10<sup>5</sup> PFU SARS-CoV-2 and sacrificed at day 4 post-infection. (<bold>B, C</bold>) Serum samples were collected for detection of anti-RBD IgG (<bold>B</bold>) and neutralizing antibody (<bold>C</bold>) against pseudovirus, respectively, at day 9 (acute, left) and day 28 (memory, right) post the 2<sup>nd</sup> immunization. The Area under the curve (AUC) represents the total peak area calculated from ELISA OD values. (<bold>D</bold>) Human ACE2 expression (green) after the Ad5-hACE2 transduction was evaluated in NT and lung by immunofluorescence (IF) staining using the hACE2-specific antibody at day-6 post-transduction. With nuclei counter staining (blue), images were shown at the 10× magnification. (<bold>E</bold>) A viral plaque assay was used to quantify infectious viruses in lung homogenates. Log<sub>10</sub>-transformed plaque-forming units (PFU) per mL of tissue extractions were shown for each group. LOD: limit of detection. (<bold>F, G</bold>) Sensitive RT PCR was used to quantify SARS-CoV-2 RdRp RNA (<bold>F</bold>) and NP subgenomic RNA (<bold>G</bold>) copy numbers (normalized by β-actin) in lung homogenates. Confocal images showed SARS-CoV-2 NP positive (red) cells (20×) in lungs (<bold>H</bold>) and NT (<bold>I</bold>) in the bright field. Mean fluorescent intensities (MFI) of NP<sup>+</sup> cells in lung and NT were measured using ImageJ software and plotted with GraphPad prism. Each symbol represents an individual mouse with consistent color-coding. Error bars indicate the standard error of the mean. Statistics were generated using one-way ANOVA followed by Tukey’s multiple comparisons test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p>
</caption>
<graphic xlink:href="EMS139869-f003"/>
</fig>
<fig id="F4" position="float">
<label>Fig. 4</label>
<caption>
<title>PD1-RBD-DNA/LAIV-HK68-RBD regime prevents SARS-CoV-2 infection in the upper and lower respiratory tracts of hACE2 transgenic mice.</title>
<p>
<bold>(A)</bold> Experimental schedule and grouping of K18-hACE-2 mice (4 mice in v1 group and 5 mice in other groups). (<bold>B, C</bold>) Serum samples were collected for detection of anti-RBD IgG (<bold>B</bold>) and neutralizing antibody (<bold>C</bold>) against pseudovirus, respectively, at day 9 (acute, left) and day 33 (memory, right) post the 2<sup>nd</sup> immunization. The Area under the curve (AUC) represents the total peak area calculated from ELISA OD values. A viral plaque assay was used to quantify infectious viruses in lung (<bold>D</bold>) and NT (<bold>G</bold>) homogenates. Log<sub>10</sub>-transformed plaque-forming units (PFU) per mL of tissue extractions were shown for each group. LOD: limit of detection. Sensitive RT PCR was used to quantify SARS-CoV-2 RdRp RNA (<bold>E, H</bold>) and NP subgenomic RNA (<bold>F, I</bold>) copy numbers (normalized by β-actin) in lung and NT homogenates. (<bold>J</bold>) Daily body weight was measured after infection. Differences between groups that were given the different vaccine regime versus PBS were determined using a 2-tailed Student’s t test. Confocal images showed SARS-CoV-2 NP positive (red) cells in lungs (10×) (<bold>K</bold>) and NT (20×) (<bold>L</bold>) in the bright field. Mean fluorescent intensities (MFI) of NP<sup>+</sup> cells in lung and NT were measured using ImageJ software and plotted with GraphPad prism. Representative images of animal lung (<bold>M</bold>) and NT (<bold>N</bold>) tissues by H&amp;E (20×). Each symbol represents an individual mouse with consistent color-coding. Error bars indicate the standard error of the mean. Statistics were generated using one-way ANOVA followed by Tukey’s multiple comparisons test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p>
</caption>
<graphic xlink:href="EMS139869-f004"/>
</fig>
<fig id="F5" position="float">
<label>Fig. 5</label>
<caption>
<title>Robust NAb and antigen-specific T cells were responsible for virus control in K18-hACE2 mice.</title>
<p>Blood samples were collected at 33 and 42 days (also 4 dpi) after the 2<sup>nd</sup> vaccination for analysis. (<bold>A, B</bold>) The mean ± SEM changes of anti-RBD IgG AUC titer (<bold>A</bold>) and neutralizing IC<sub>50</sub> values (<bold>B</bold>) were determined by anti-RBD IgG ELISA and pseudovirus assay, respectively. (<bold>C</bold>) Lung CD8 T cells were assayed for IFN-γ expression by flow cytometry after re-stimulated with the RBD peptide pool. Tissue-resident memory CD8 T cells (TRM) in lungs were phenotyped for expression CD69 and CD103 (<bold>D</bold>) and the IFN-γ producing TRM were measured by re-stimulated with the RBD peptide pool (<bold>E</bold>). (<bold>F</bold>) Viral load (relative gRdRp) in lungs correlated with NAb IC<sub>50</sub> titer or percentage of IFN-γ producing CD8 T cells. NP<sup>+</sup> cells (MFI) in lungs correlated with NAb IC<sub>50</sub> titer or percentage of IFN-γ producing CD8 T cells. (<bold>G</bold>) Viral load (relative gRdRp) in NT correlated with NAb IC<sub>50</sub> titer or percentage of IFN-γ producing CD8 T cells. NP<sup>+</sup> cells (MFI) in NT correlated with NAb IC<sub>50</sub> titer or percentage of IFN-γ producing CD8 T cells. Correlation analysis was performed by linear regression using GraphPad Prism 8.0. Each color represents a vaccination regimen. Each symbol represents an individual mouse. Statistics were generated using the 2-tailed Student’s t test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p>
</caption>
<graphic xlink:href="EMS139869-f005"/>
</fig>
<fig id="F6" position="float">
<label>Fig. 6</label>
<caption>
<title>Combinations of systemic and mucosal immunization induce robust humoral and cellular immune responses in the effector site.</title>
<p>Experimental schedule and grouping of BALB/c mice (5 mice per group). Blood (<bold>B, E</bold>) and bronchoalveolar lavage (BAL) (<bold>C, D, F</bold>) were collected and subjected to RBD-specific IgG (<bold>B, C</bold>) or IgA (<bold>D</bold>) detection and NAb IC<sub>50</sub> activity (<bold>E, F</bold>). The area under the curve (AUC) represented the total peak area calculated from ELISA OD values. Neutralization IC<sub>50</sub> values were determined against SARS-CoV-2-Spike-pseudovirus infection of 293T-huACE2 cells. (<bold>F</bold>) Lung CD8 T cells were assayed for IFN-γ expression by flow cytometry after re-stimulated with the RBD peptide pool. Tissue-resident memory CD8 T cells (TRM) in lungs were phenotyped for expression CD69 and CD103 (<bold>G</bold>) and the IFN-γ producing TRM were measured by re-stimulated with the RBD peptide pool (<bold>H</bold>). Each colour represents a vaccination regimen. Each symbol represents an individual mouse. Statistics were generated using the 2-tailed Student’s t test. *p&lt;0.05; **p&lt;0.01; ***p&lt;0.001.</p>
</caption>
<graphic xlink:href="EMS139869-f006"/>
</fig>
<fig id="F7" position="float">
<label>Fig. 7</label>
<caption>
<title>Cross-neutralization of vaccine-induced systemic and mucosal NAb against SARS-CoV-2 variants.</title>
<p>Neutralization activities of immune sera (<bold>A-B</bold>) and BAL (<bold>C-D</bold>) elicited by various vaccine regimens (same as described in <xref ref-type="fig" rid="F6">Fig. 6</xref>) were determined against 3 color-coded pseudoviruses in 293T-ACE2 cells. Data showed mean±SEM of 5 mice in each vaccine group. (<bold>B and D</bold>) Comparison of mean IC<sub>50</sub> values against different SARS-CoV-2 variants (left) and fold-change of mean IC<sub>50</sub> values in relation to the SARS-CoV-2 D614G strain (right).</p>
</caption>
<graphic xlink:href="EMS139869-f007"/>
</fig>
</floats-group>
</article>
